{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:25:14Z","timestamp":1770722714835,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","urologypracticejournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.urpr.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T12:45:35Z","timestamp":1481373935000},"page":"31-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Review Article: Is There a Role for Antifibrotics in the Treatment of Urological Disease? A Systematic Review of the Literature"],"prefix":"10.1097","volume":"5","author":[{"given":"Omer A.","family":"Raheem","sequence":"first","affiliation":[{"name":"Department of Urology, University of California San Diego School of Medicine, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash S.","family":"Khandwala","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Chin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California San Diego School of Medicine, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill C.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California San Diego School of Medicine, La Jolla, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.urpr.2016.11.011_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7326\/0003-4819-152-3-201002020-00007","article-title":"Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies","volume":"152","author":"Rosenbloom","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urpr.2016.11.011_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12016-009-8157-7","article-title":"Antifibrosis: to reverse the irreversible","volume":"38","author":"Paz","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.urpr.2016.11.011_bib3","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie\u2019s disease experimental studies","volume":"10","author":"Gelbard","year":"1982","journal-title":"Urol Res"},{"key":"10.1016\/j.urpr.2016.11.011_bib5","first-page":"2822","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie\u2019s disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.urpr.2016.11.011_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urpr.2016.11.011_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1756287214537331","article-title":"Experience in the use of collagenase clostridium histolyticum in the management of Peyronie\u2019s disease: current data and future prospects","volume":"6","author":"Egui Rojo","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib8","first-page":"380","article-title":"A\u00a0comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome","volume":"189","author":"Chung","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"suppl.","key":"10.1016\/j.urpr.2016.11.011_bib9","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijir.3900558","article-title":"Inhibition of Peyronie\u2019s plaque fibroblast proliferation by biologic agents","volume":"12","author":"Anderson","year":"2000","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urpr.2016.11.011_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urpr.2016.11.011_bib11","first-page":"621","article-title":"Experience with intraplaque injection of verapamil for Peyronie\u2019s disease","volume":"168","author":"Levine","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.eururo.2007.06.036","article-title":"Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie\u2019s disease","volume":"53","author":"Haag","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib13","first-page":"1342A","article-title":"Interferon alpha-2b in the treatment of Peyronie\u2019s disease","volume":"145","author":"Benson","year":"1991","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib14","first-page":"394","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon\u202f\u03b1-2b for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urpr.2016.11.011_bib16","first-page":"745","article-title":"Peyronie\u2019s disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1464-410X.2004.05151.x","article-title":"Bladder neck contracture after radical retropubic prostatectomy","volume":"94","author":"Besarani","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urpr.2016.11.011_bib18","first-page":"156","article-title":"Radial urethrotomy and intralesional mitomycin C for the management of recurrent bladder neck contractures","volume":"186","author":"Vanni","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib19","first-page":"587","article-title":"Intralesional injection of mitomycin C at transurethral incision of bladder neck contracture may offer limited benefit: TURNS Study Group","volume":"193","author":"Redshaw","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.urpr.2014.12.007","article-title":"Durable results of mitomycin C injection with internal urethrotomy for refractory bladder neck contractures: multi-institutional experience","volume":"2","author":"Nagpal","year":"2015","journal-title":"Urol Pract"},{"key":"10.1016\/j.urpr.2016.11.011_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"a clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urpr.2016.11.011_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.urpr.2015.08.009","article-title":"Therapeutic use of mitomycin C for urological conditions: systematic review of the literature","volume":"3","author":"Raheem","year":"2016","journal-title":"Urol Pract"},{"key":"10.1016\/j.urpr.2016.11.011_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/01.MLG.0000205590.62824.0A","article-title":"Effects of mitomycin-C on normal dermal fibroblasts","volume":"116","author":"Chen","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.urpr.2016.11.011_bib24","first-page":"182","article-title":"Male urethral stricture: American Urological Association guideline","volume":"197","author":"Wessells","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1464-410X.2004.05088.x","article-title":"Management of urethral stricture disease: developing options for surgical intervention","volume":"94","author":"Peterson","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urpr.2016.11.011_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.eururo.2006.11.038","article-title":"Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy","volume":"51","author":"Mazdak","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-4165(93)90123-P","article-title":"Halofuginone: an inhibitor of collagen type I synthesis","volume":"1156","author":"Granot","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.urpr.2016.11.011_bib28","first-page":"1776","article-title":"The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in\u00a0vivo and in\u00a0vitro study in a rat model","volume":"164","author":"Nagler","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib29","first-page":"2049","article-title":"The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits","volume":"170","author":"Jaidane","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/end.2010.0514","article-title":"Halofuginone-coated urethral catheters prevent periurethral spongiofibrosis in a rat model of urethral injury","volume":"25","author":"Krane","year":"2011","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.urpr.2016.11.011_bib31","first-page":"1507","article-title":"An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids","volume":"34","author":"Koc","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.urpr.2016.11.011_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1464-410X.1967.tb09823.x","article-title":"Balanitis xerotica obliterans: effective treatment with topical and sublesional corticosteroids","volume":"39","author":"Poynter","year":"1967","journal-title":"Br J Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000473209","article-title":"Optical internal urethrotomy for strictures of the male urethra. Effect of local steroid injection","volume":"7","author":"Hradec","year":"1981","journal-title":"Eur Urol"},{"key":"10.1016\/j.urpr.2016.11.011_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF02550404","article-title":"Intralesional corticosteroid injections in combination with internal urethrotomy in the treatment of urethral strictures","volume":"22","author":"Korhonen","year":"1990","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urpr.2016.11.011_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11255-009-9663-5","article-title":"Internal urethrotomy and intraurethral submucosal injection of triamcinolone in short bulbar urethral strictures","volume":"42","author":"Mazdak","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urpr.2016.11.011_bib36","first-page":"132","article-title":"Triamcinolone injection following internal urethrotomy for treatment of urethral stricture","volume":"8","author":"Tavakkoli Tabassi","year":"2011","journal-title":"Urol J"},{"key":"10.1016\/j.urpr.2016.11.011_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1464-410X.2011.10733.x","article-title":"Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie\u2019s disease: a phase I study","volume":"110","author":"Pavone","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urpr.2016.11.011_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urpr.2016.11.011_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/00365590600917974","article-title":"Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat","volume":"41","author":"Shirazi","year":"2007","journal-title":"Scand J Urol Nephrol"}],"container-title":["Urology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352077916302801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352077916302801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.urpr.2016.11.011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:43:56Z","timestamp":1651196636000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.urpr.2016.11.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1016\/j.urpr.2016.11.011"],"URL":"https:\/\/doi.org\/10.1016\/j.urpr.2016.11.011","relation":{},"ISSN":["2352-0779"],"issn-type":[{"value":"2352-0779","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review Article: Is There a Role for Antifibrotics in the Treatment of Urological Disease? A Systematic Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Urology Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urpr.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by American Urological Association Education and Research, Inc.","name":"copyright","label":"Copyright"}]}}